Case Study: How the XtalPi Team Discovered Novel, Non-Covalent, Potent Hits Against GPX4 in 28 Days

GPX4 is a critical enzyme for cellular antioxidant defense, but is a highly challenging target. In this case study, we share the story of how we discovered three novel non-covalent hit compounds with biochemical IC₅₀?< 10μM in just 28 days.

• Using predictive AI models and physics-based computations, we probed key pharmacophores with high accuracy and throughput, even without reference compounds.
• 159 library compounds were proposed and 124 were successfully synthesized using our automation platform.